Where I see patients (1)
My reviews
Selected research
-
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Blood advances
-
Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies.
Cancer medicine
-
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Blood advances
Clinical trials
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421
4.9